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Abstract
Background. Giant cell glioblastoma (gcGBM) is a rare histologic subtype of glioblastoma characterized by numerous bizarre multinucleate giant cells and increased reticulin deposition. Compared with conventional isocitrate
dehydrogenase (IDH)-wildtype glioblastomas, gcGBMs typically occur in younger patients and are generally associated with an improved prognosis. Although prior studies of gcGBMs have shown enrichment of genetic events,
such as TP53 alterations, no defining aberrations have been identified. The aim of this study was to evaluate the
genomic profile of gcGBMs to facilitate more accurate diagnosis and prognostication for this entity.
Methods. Through a multi-institutional collaborative effort, we characterized 10 gcGBMs by chromosome studies,
single nucleotide polymorphism microarray analysis, and targeted next-generation sequencing. These tumors
were subsequently compared to the genomic and epigenomic profile of glioblastomas described in The Cancer
Genome Atlas (TCGA) dataset.
Results. Our analysis identified a specific pattern of genome-wide massive loss of heterozygosity (LOH) driven
by near haploidization in a subset of glioblastomas with giant cell histology. We compared the genomic signature
of these tumors against that of all glioblastomas in the TCGA dataset (n = 367) and confirmed that our cohort of
gcGBMs demonstrated a significantly different genomic profile. Integrated genomic and histologic review of the
TCGA cohort identified 3 additional gcGBMs with a near haploid genomic profile.
Conclusions. Massive LOH driven by haploidization represents a defining molecular hallmark of a subtype of
gcGBM. This unusual mechanism of tumorigenesis provides a diagnostic genomic hallmark to evaluate in future
cases, may explain reported differences in survival, and suggests new therapeutic vulnerabilities.

Key Points
1. A subset of giant cell glioblastomas (gcGBM) show genome-wide loss of heterozygosity.
2. This genomic signature could improve diagnosis and prognostication in gcGBM.
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Importance of the Study
Giant cell glioblastoma (gcGBM) is a rare subtype of IDH-wildtype glioblastoma with an
improved prognosis relative to non-giant cell
counterparts. Herein, we describe a cohort of
10 gcGBMs with a unique genomic signature
of genome-wide massive loss of heterozygosity consistent with haploidization. As the

infiltrative than conventional glioblastoma and may mimic
both non-neoplastic and neoplastic entities, such as infarct,
hemorrhage, and metastatic disease.10 Demographically,
patients with gcGBM present at a younger median age and
are more likely to receive complete resection.2 Notably, the
majority of published studies on adult tumors indicate a
more favorable prognosis in gcGBM compared to other
IDH-wildtype GBMs.2–5,11 In one of the larger retrospective
case series examining gcGBM patients, long-term survival
(greater than 5 years) occurred nearly 4 times as often as in
conventional non-gcGBM.2
Herein, we describe an interinstitutional genomic analysis of a cohort of 10 gcGBMs, which display a molecular
signature distinctive from IDH-wildtype GBMs, showing
massive genome-wide loss of heterozygosity (LOH). Our
results suggest this genomic profile may represent the
genomic hallmark of a subset of these entities, providing
a novel molecular signature for improved diagnostics.
Furthermore, these findings provide evidence of an unusual mechanism of tumorigenesis with the potential to
reveal prognostic implications and/or new therapeutic
strategies.

Materials and Methods
Case Selection and Clinical Features
Following the identification of 2 index cases, the archives
of multiple institutions (Brigham and Women’s Hospital
and Harvard Medical School, Children’s Mercy Hospital
and University of Missouri-Kansas City School of Medicine,
Laboratory Corporation of America® Holdings, and the
Medical University of South Carolina) were searched for
newly diagnosed GBMs that demonstrated both genomewide massive LOH and characteristic histology consistent
with gcGBMs. Out of a total of 768 GBMs, 17 additional
cases were identified that showed some degree of giant
cell morphology; 8 of those demonstrated massive LOH
as observed in the index cases. Postsurgical diagnostic
workup for the purpose of routine clinical care for each case
included histologic review of hematoxylin and eosin (H&E)
stained slides, variable degrees of immunohistochemical
profiling, and genetic characterization with some combination of chromosome analysis (n = 2), chromosomal microarray testing (n = 10), next-generation sequencing (NGS)
(n = 7), and O6-methylguanine-DNA methyltransferase
(MGMT) promotor methylation studies (n = 6).
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Recent molecular advances have revolutionized taxonomic classification among tumors of the CNS as evidenced by the introduction of the integrated molecular and
histopathologic diagnoses in the 2016 update of the WHO
classification of CNS tumors.1 This shift in diagnostic paradigm emphasizes the importance of molecular findings
in the evaluation of these tumors and ensures they are
placed into the most appropriate diagnostic and prognostic
categories. For instance, among diffuse gliomas, the presence of an isocitrate dehydrogenase (IDH) mutation implies
a much-improved prognosis over IDH-wildtype tumors with
similar histologic features. Similarly, formal incorporation
of 1p/19q codeletion status permits the distinction between
oligodendroglioma and astrocytoma on a purely molecular
basis. The term “glioblastoma,” however, remains a broader
diagnostic entity for any diffuse astrocytic tumor with highgrade histopathologic features.
Giant cell glioblastoma (gcGBM) is a rare histological
variant of glioblastoma comprising approximately 1%
of adult cases.2–4 In addition to the usual histologic features of glioblastoma (GBM) (eg, astrocytic morphology,
elevated proliferative rate, endothelial proliferation, and
necrosis), gcGBM features bizarre, pleomorphic, and
variably multinucleated giant cells and increased reticulin content.1 Like other histologic subtypes of GBM,
no defining genomic features have thus far been identified. Attempts to characterize the molecular genetics
of gcGBM have been challenged by rarity and use of
targeted (rather than genome-wide) genomic analyses.
However, in the limited work that has been published,
enrichment of mutations in a small number of genes,
including TP53, PTEN, RB1, and ATRX, coupled with an
overall low tumor mutational burden has been noted.1,5,6
One study, however, showed an association between
mismatch repair deficiency and giant cell morphology
in a small cohort of GBMs.7 Additionally, a potential link
has been made between gcGBMs and POLE mutations.7,8
Furthermore, certain copy number variations that occur
more frequently in conventional glioblastoma, such
as EGFR amplification and CDKN2A homozygous deletions, are much less frequent or absent in gcGBM.1,5,6
While gcGBMs have been shown to be vulnerable to
DNA damage due to a higher propensity for DNA double
strand breaks,9 the underlying molecular mechanisms
unique to gcGBM remain unknown.
Although mostly limited to case reports, existing evidence suggests unique clinical behavior and presentation in gcGBM. Radiographically, gcGBM appears less

current classification of gcGBM is based entirely on histomorphology, use of this genetic
profile in conjunction with histomorphologic
features may aid in assuring these rare lesions
are placed into appropriate diagnostic, prognostic, and therapeutic categories now and in
the future.
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Chromosomal Microarray

Next-Generation Sequencing
Targeted exome sequencing using a custom hybrid capture
NGS assay (OncoPanel) was performed on DNA isolated
from FFPE tissue as described previously13 for a subset of
cases or using a hotspot mutation detection panel as previously described.14

TCGA Data
GBM copy number and LOH calls were extracted from
The Tissue Cancer Genome Atlas (TCGA) for GBM (TCGA,
PanCancer Atlas) dataset from https://gdc.cancer.gov/
about-data/publications/pancanatlas.
Percentage
of
genome-wide LOH was calculated using autosomes. DNA
methylation data were obtained across a subset of samples available from the TCGA, including both IDH-mutant
and IDH-wildtype tumors. Hierarchical clustering of the
top 3000 differentially methylated probesets was performed using MeV software(mev.tm4.org) as previously
described.15

Statistical Analysis
Statistical Analysis was performed using Prism 8.
Differences in the frequency of copy number alterations
and mutations were computed using a Fisher Exact test
in our cohort of gcGBMs versus all GBMs in the TCGA
dataset.
This study was conducted with Institutional Review
Board approval at Brigham and Women’s Hospital,
Boston, MA, and at Children’s Mercy Hospital, Kansas
City, MO.
Microarray data used in this study are accessible in the
Gene Expression Omnibus (GSE157647).

Demographic, Clinical, and Radiologic Features
of gcGBM
Our cohort consisted of 10 patients, for which variable clinical information was available for 9 (9/10), included 4 (4/9)
female and 5 (5/9) male patients ranging in age from 9 to
68 years. All tumors were located in the cerebral hemispheres, and 7 (7/9) tumors were located in the frontal lobe
with 2 (2/9) located in the temporal lobe. Most patients (8/9)
had solitary lesions. Most cases (7/9) showed well circumscribed, contrast-enhancing lesions (Figure 1A) prompting
radiologic differential diagnoses that predominantly included metastatic disease and high-grade glial neoplasms.
One patient possessed a germline TP53 mutation consistent with Li-Fraumeni syndrome. MGMT analysis was
performed for 6 cases, 3 (3/6) of which demonstrated methylated promoter regions.
The clinical features of the cohort are summarized in
Table 1.

Pathologic Features
Slides were available for review for 9 (9/10) cases, all of
which displayed typical histopathologic features of gcGBM
(Table 2; Figure 1; Supplementary Figure S1), characterized by the presence of extremely large multinucleate
tumor cells distributed throughout the tumors. In one case
(gcGBM8), central review of the morphology was not possible; however, the accompanying pathology report indicated predominant giant cell morphology. The giant cells
identified in each case were markedly pleomorphic and
contained variable numbers of nuclei with prominent nucleoli, frequent nuclear pseudoinclusions, and voluminous eosinophilic cytoplasm (Figure 1B; Supplementary
Figure S1). Interspersed mononuclear tumor cells showed
typical high-grade astrocytic appearance, frequently exhibiting epithelioid (9/9 cases) or spindled (4/9 cases) morphology reminiscent of gliosarcoma (not shown). Vascular
proliferation and necrosis were ubiquitous. Large regions of geographic, infarct-type necrosis were common
in larger samples (5/9 cases; Figure 1E; Supplementary
Figure S1B,F,J,L). The mitotic activity was moderate, ranging from 5 to 18 per high power field, often with atypical
mitotic forms. The Ki-67 index ranged from 21 to 60 percent. Of note, eosinophilic granular bodies were identified in 3/9 cases (Figure 1F); however, no Rosenthal
fibers were observed. Of those tumors with surrounding
normal brain tissue, 3/5 demonstrated sharp demarcation with minimal infiltration (Figure 1C; Supplementary
Figure S1D,G). Robust perivascular and intratumoral
lymphocytic inflammation was also a common feature,
noted in all 9 cases (Figure 1D, Supplementary Figure S1).
Immunohistochemistry for glial markers, such as GFAP,
was uniformly positive.
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Formalin-fixed,
paraffin-embedded
(FFPE)
tissue
was acquired for chromosomal microarray analysis.
H&E-stained slides corresponding to the FFPE tissue
blocks were examined by a board-certified neuropathologist to select optimal tissue regions. The analysis
was performed on multiple platforms including the
Infinium CytoSNP-850K BeadChip array, ThermoFisher
OncoScanTM CNV Plus, and Agilent 1x1M as previously
described.12,13 Copy number changes were reported relative to the inferred tumor ploidy.

Results

Neuro-Oncology
Advances

The patient’s age and sex, anatomic location of tumor,
sampling modality (biopsy vs resection), treatment regimen, radiologic appearance of tumor at presentation, and
status of the patient at last follow-up (alive without evidence of recurrence, alive with recurrent disease, or deceased) were recorded where available.
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Figure 1. Giant cell glioblastoma (gcGBM) demonstrates specific radiographic and histological features. (A) T2-weighted MRI of gcGBM in left
frontal lobe demonstrating the circumscribed nature of the tumor. (B) H&E-stained tissue section of gcGBM demonstrating the high degree of tumor
cell pleomorphism, along with the presence of giant and/or multinucleated tumor cells. (C) At lower magnification, many tumors are remarkably
nodular and do not exhibit diffuse infiltration into adjacent normal brain tissue. (D) Dense perivascular and intratumoral lymphocytic inflammation is
common in gcGBM. (E) Many tumors showed large regions of coagulative necrosis (dotted line indicates boundary between viable tumor on the left
and infarcted tumor on the right). (F) Occasional tumors contained focal eosinophilic granular bodies (arrows). Scale bars = 25 µm in B and F, 50 µm
in D and E, 100 µm in C.
  

gcGBMs Demonstrate Consistent Genome-Wide
Loss of Heterozygosity
Combinatorial use of microarray analysis and NGS revealed a remarkably consistent copy number profile with a
relative gain of chromosome 7, observed in all tumors, and
frequent gains of 1q and chromosome 16 (Figure 2A). No
focal copy number aberrations (eg, EGFR amplification or
homozygous CDKN2A deletion) were identified, and broad
homozygous copy number losses were rare. Notably,
allele-specific copy number profiling demonstrated a
striking pattern of copy-neutral LOH affecting between 54%
and 94% of the genome, with universal retention of heterozygosity of chromosome 7 (Figure 2B, Supplementary
Figure S2). This observation, in the absence of a concomitant copy number loss, is most consistent with genomic
near-haploidization. Chromosome studies confirmed this
hypothesis by demonstrating a haploid karyotype with retention of 2 copies of chromosomes 7 in 2 tumors that were
evaluated by this methodology (Figure 2C, Supplementary
Figure S3). Moreover, these studies also noted frequent
endoreduplication of the haploid clone leading to a near
diploid state (Figure 2D).

gcGBMs Demonstrate a Distinct Copy Number
Profile From Non-gcGBMs
To evaluate the specificity of these findings, we compared
the genomic profile of our tumors against a broader cohort of GBMs, both IDH-wildtype and mutated, for which

similarly comprehensive genomic data exists. To this end,
we first evaluated the genome-wide copy number profile
of our cohort against that of all GBMs present in the TCGA
database (n = 367). While both cohorts shared several aberrations, including copy number gain of chromosome 7, the
profiles were otherwise remarkably distinct (Figure 3A).
The gcGBMs in our cohort demonstrated significantly
fewer copy number aberrations on average relative to
other GBMs (24 vs 103, P < .001; Figure 3B); however, these
aberrations were significantly larger on average (115.2 Mb
vs 36.10 Mb, P < .0001) and generally included whole chromosome or arm level events (Figure 3C). Moreover, there
was a striking absence of focal aberrations, such as EGFR
amplifications, homozygous deletions of CDKN2A/2B,
and relative loss of chromosome 10, which are commonly
observed in GBMs. Most striking were differences in
genome-wide copy-neutral LOH. While LOH (copy neutral
or copy-number driven) was observed in all gcGBMs (ranging from 54% to 94% of the autosomal haploid genome;
average 79%), similar levels of LOH were noted in only
1% (3/367) of GBMs in the TCGA dataset (Figure 3D, pink
dots). Review of the scanned slide images of all 3 TCGA
cases with massive LOH revealed clear gcGBM histology
as described above.

gcGBM Demonstrates Distinct Mutational Profile
and Epigenetic Signature From Non-gcGBM
While the mutational profile of gcGBM has been previously
described,1,5,6 given the unexpected and unreported nature
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Summary of the Demographics and Clinical Parameters of the gcGBM Cohort
Gender

Age
(years)

MGMT Promoter Status

Resection
Type

Location

Circumscribed on
Imaging

Adjuvant
Therapy

Status at Last
Follow-up
(months)

gcGBM1

Female

24

Unmethylated

Near gross
total

Left frontal

Yes

RT and
Optune

AWOD (18)

gcGBM2

Male

55

N/A

N/A

Right
frontal

Yes

N/A

N/A

gcGMB3

Male

68

Methylated

Stereotactic
biopsy

Left frontal

Yes

TMZ/RT

DOD (9)

gcGBM4

Male

57

Methylated

Near gross
total

Right
frontal

Yes

TMZ/RT

AWOD (8)

gcGBM5

Male

50

Methylated

Near gross
total

Right
frontal

No

TMZ/RT

AWD (15)

gcGBM6

Female

9

N/A

Near gross
total

Right temporal

Yes

TMZ/RT

DOD (20)

gcGBM7

Female

12

N/A

Near gross
total

Left frontal

Yes

TMZ/RT

DOD (41)

gcGBM8

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

gcGBM9

Male

57

Unmethylated

Near gross
total

Right temporal

Yes

N/A

AWOD (1)

gcGBM10

Female

48

Unmethylated

Near gross
total

Left frontal

Yes

TMZ/RT

DOD (14)

AWD, alive with recurrent disease; AWOD, alive without recurrent disease; DOD, died of disease; N/A, not available; RT, radiation therapy; TMZ,
temozolomide.

  
of the copy number landscape driven by a near-haploid
profile, we evaluated recurrent mutations observed in
gcGBMs from our cohort (including the 3 tumors reclassified as gcGBMs from the TCGA dataset) against the remaining non-gcGBMs in the TCGA dataset. In keeping with
previous reports, we observed a significantly higher frequency of mutations in TP53 (87.5% vs 28.5%; P < .0011) and
RB1 (75% vs 8.65%; P < .0001; Figure 3E, Supplementary
Table S1). Other commonly mutated genes included PTEN
(50%), NF1 (30%), and PIK3CA (10%). Of note, no alterations
were detected in TERT promoter region in 5 of 5 tumors
for which this region was analyzed. Finally, we evaluated
the epigenetic signature of gcGBMs (from TCGA tumors
where this information was available) against a subset of
TCGA GBMs (n = 17), including both IDH-wildtype and IDHmutated tumors. Hierarchical clustering only convincingly
demonstrated 2 distinct subgroups, differentiating IDHmutated from IDH-wildtype tumors. While 2 of the 3 TCGA
gcGBMs cluster most closely together, the epigenetic profile was not significantly different from that observed in
other IDH-wildtype GBMs (Figure 3F).

  
Table 2. Summary of the Histopathologic Features of the gcGBM
Cohort
Features

N/Total (%)

Giant multinucleate cells

9/9 (100)

Mononuclear epithelioid cells

9/9 (100)

Spindled cells

4/9 (44)

Perivascular/intratumoral inflammation

9/9 (100)

Eosinophilic granular bodies

3/9 (33)

Nuclear pseudoinclusions

9/9 (100)

Vascular proliferation

9/9 (100)

Necrosis

9/9 (100)

Geographic/coagulative necrosis

5/9 (56)

Atypical mitotic figues

9/9 (100)

Nodular/well-demarcated growth

3/5 (60)

Mitotic count (range) (per 10 HPF)

5–18

Ki67 index (range) (%)

21–60

HPF, High power fields.

TP53 Alterations May Drive Giant Cell Histology
in the Absence of a Near-Haploid Profile
As prior studies have described variability in the degree
to which giant cell features can be observed in GBMs,
we performed a comprehensive evaluation of 768 GBMs
and identified 9 additional cases in which the presence
of giant cells were noted by histopathology report.
While these tumors exhibited giant cell features, these

  
were frequently rare or scattered, rather than the predominant pattern observed in near-haploid gcGBMs
(Supplementary Figure S4A). In each of these additional
cases, allele-specific copy number profile did not identify a near-haploid signature (Supplementary Figure
S4B,C) but instead a copy number profile more reminiscent of IDH-wildtype GBMs, with the presence of
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A
Log2 ratio

gcGBM-7
1.0
0.8
0.6
0.4
0.2
0
–0.2
–0.4
–0.6
–0.8
–1.0

1

2

3

4

5

6

7

8

9

10
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13
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16 17 18 19 20 2122

11

12

13
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15

16 17 18 19 20 2122

Relative CN gain

Relative CN loss

B
gcGBM-7
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

1

2

3

4

5

6

7

8

9

10

gcGBM-1
gcGBM-2
gcGBM-3
gcGBM-4
gcGBM-5
gcGBM-6
gcGBM-7
gcGBM-8
gcGBM-9
gcGBM-10
Loss of heterozygosity

C
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D

1

2

3

6

7

8

13

14
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19

20
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4

9

16

22

10

5

11

17

1

2

3

12

6

7

8
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14

15
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21

X

4

9

16

22

5

10

11

17

12

18

X

Figure 2. Near haploidization as a genomic hallmark of giant cell glioblastomas (gcGBMs). (A) Relative copy number landscape of gcGBMs. (B)
Loss of heterozygosity (LOH) analysis of gcGBMs. (C) Stemline haploid clone identified by chromosome analysis of gcGBM7. (D) Doubled haploid
clone detected in gcGBM7.
  

amplification events involving EGFR or MDM2, CDKN2A
homozygous deletion, or monosomy 10. Notably, targeted molecular studies demonstrated that in 8 (8/9)
of these additional cases in which TP53 sequencing
was performed, an oncogenic alteration was identified
(Supplementary Figure S5).

Treatment and Outcomes
Of 8 patients with near-haploid gcGBM, sufficient
available surgical history, 7 received near total resections, and one underwent biopsy, alone. Of the 7 patients with available treatment history, 6 received
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A
gcGBM (n = 10)

TCGA GBM (n = 367)

3

5

6

7

8

9

10

C

P<0.001

gcGBM
GBM

0.015

300
200

0.010
0.005

100

0

0

gcGBM

0

GBM

11

12

13

14

15

16 17 18 19 20 2122

D
0.020

400

Density

Number of copy number aberrations
(CNAs)

4

50
100
150
200
250
Size of copy number aberrations (Mbs)

P<0.001

75
50
25
0
gcGBM

GBM

F
P<0.0001

P<0.0001

E

NS

NS

NS

NS

NS

Mutation frequency (%)

75
gcGBM
50

GBM, IDHwt
GBM, IDHmut

25

0

% methylation

100

0
TP53

RB1

PTEN

NF1 PIK3CA EGFR ATRX

gcGBM
GBM

Figure 3. Genomic characterization of giant cell glioblastomas (gcGBMs) versus The Cancer Genome Atlas (TCGA) GBMs. (A) Summary plot of
copy number analysis across gcGBM (n = 10) cohort versus TCGA GBMs (n = 367). (B) Frequency of copy number aberration in gcGBMs versus
TCGA GBMs (C) Density plot analysis of copy number size distribution of gcGBMs versus TCGA GBMs. (D) Genome-wide loss of heterozygosity
analysis. (E) Frequency of mutations observed in gcGBM cohort. (F) Hierarchical clustering analysis of gcGBMs versus isocitrate dehydrogenase
(IDH)-wildtype and IDH-mutated GBMs in the TCGA cohort.
  

standard postoperative radiation and temozolomide
chemotherapy, and 1 received only postoperative radiation therapy. Reported patient statuses at last follow-up were the following: alive without evidence of
recurrence (3 patients), alive with recurrent disease (1
patient), or deceased (4 patients). Patient survival information was limited by several patients being lost to
follow up but ranged from 1 to 41 months for the 8 patients where available (summarized in Table 1).

Discussion
gcGBM is a rare subtype of IDH-wildtype GBM, with
marked differences in its histological, radiographical, and
clinical presentation. Histologically, these tumors are set
apart by their circumscribed appearance, increased reticulin deposition, and the presence of pleomorphic and
multinucleated tumor giant cells. Despite numerous
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highlights the importance of marrying a homogenous histopathology diagnosis with an underlying genomic signature. For example, Cantero et al. investigated tumors with a
histopathology diagnosis of gcGBM together with tumors
demonstrating a giant cell component.5 While all tumors
in their study shared alterations in TP53 and some degree
of giant cell features, several cases showed additional genetic drivers, such as IDH1/2 or BRAF mutations. As IDH1/2
mutation status is an important diagnostic marker, which
describes both clinical behavior and underlying biology,
the inclusion of these tumors in this study highlights the
inherent limitation of the current histological criteria. Thus,
while p53 deficiency may be an important component
driving elements of a giant cell morphology in a subset of
tumors, the link between p53 function, near-haploidy, and
gcGBM morphology appears much more compelling.
While generally accepted to be a rare mechanism of tumorigenesis, near-haploidy is commonly encountered
as a rare but recurrent observation across a wide array
of tumors, including inflammatory leiomyosarcoma,17
oncocytic follicular thyroid carcinoma/Hürthle cell carcinoma,18,19 adrenocortical carcinoma,20 and peripheral
chondrosarcoma.21 In these lesions, near-haploidy can be
viewed as a defining feature either for the entity or for its
clinical behavior. For instance, the genome-wide loss of
chromosomes resulting in a near-haploid state correlates
with the malignant evolution of osteochondroma to lowgrade chondrosarcoma, and subsequent polyploidization
or reduplication of those chromosomes marks further
transformation to high-grade chondrosarcoma.21 This
series of genomic events is recapitulated in many of the
above-mentioned tumor types, serving as a unique mechanism of tumor evolution.17,18,20,22 The resultant widespread
loss of chromosomes has been broadly hypothesized to
provide a mechanism whereby many tumor suppressors
are lost in one catastrophic event, likely early in tumorigenesis. In support of this hypothesis, a statistically significant association between an increased rate of tumor
suppressor mutations and massive LOH has been demonstrated in Hürthle cell carcinoma.23
Notably, all gcGBMs evaluated in our study retained heterozygosity of chromosome 7. This pattern was previously
demonstrated in the first description of gcGBM with near
haploidization and is a commonly reported signature in tumors with massive LOH.16,19,23 In addition, the ubiquitous
preservation of heterozygosity suggests that tumor survival may be dependent on adequate gene dosage. One
publication lends support to the hypothesis that imprinted
genes necessary for cancer cell survival are present on
chromosome 7, necessitating its heterozygosity.24
The histopathologic features of our cohort closely
mirror those described in previous reports and the WHO
classification schema for gcGBM.1 Nonetheless, several clinicopathologic findings draw inevitable comparison with pleomorphic xanthoastrocytoma (PXA),
especially high-grade or “anaplastic” variants. Tumors
often occur in a young patient demographic, have a wellcircumscribed appearance, and show overlapping microscopic features that include bizarre pleomorphism,
reticulin deposition, perivascular lymphocytic inflammation, and occasional eosinophilic granular bodies.
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efforts to identify defining genomic, or epigenomic features, no diagnostically specific findings have been identified. These studies have, however, reported frequent
inactivation of TP53, which was postulated by one group
to be a driver event,5,6 in addition to confirming their
IDH-wildtype status.
Herein, we present a cohort of 10 gcGBMs with massive
LOH, all of which display near-haploidization, suggesting
this event represents a molecular hallmark of at a distinct
subset of gcGBMs. The identification of this genomic signature provides, for the first time, an ability to link the
histomorphology appearance of these tumors with an underlying molecular signature, thus providing the potential
for future adoption of an integrated diagnosis. We validated our findings by comparing our cohort against 367
GBMs from the TCGA database. This analysis revealed a
distinct copy number landscape in gcGBMs compared to
other glioblastomas, with gcGBM demonstrating gains of
chromosome 7, as well as frequent gains of chromosomes
1q and 16, but lacking focal aberrations, such as EGFR amplification and CDKN2A homozygous deletion, which are
frequently detected in non-gcGBMs. Importantly, allelespecific copy number analysis identified a pattern of near
genome-wide LOH consistent with a near-haploid state.
Moreover, performing this analysis on the TCGA GBM
dataset led to the identification of 3 additional gcGBMs
(3/367), a compelling testament to the observations reported herein. This serendipitous finding resulted solely
from comparison of the proportion of the genomes affected by LOH; the histopathologic features of gcGBM
were discovered secondarily. Although the presence of undiscovered gcGBMs lacking massive LOH in TCGA remains
possible, the previously reported incidences of gcGBM are
comparable to what was observed in TCGA, 0.8%.2–4
We also characterized the mutational and epigenetic
landscape of these tumors. Similar to previously descriptions, gcGBMs demonstrate frequent oncogenic variants
in the tumor suppressors TP53 and RB1.1,5,6 Furthermore,
using epigenetic data available for gcGBMs from the TCGA
database, we performed methylation analysis, which
convincingly differentiated gcGBMs from IDH-mutated
GBMs. While gcGBMs largely clustered together, the signature was not sufficiently robust to consistently differentiate these entities from other IDH-wildtype GBMs. Future
studies with larger sample size should be dedicated to the
methylation signatures of giant cell glial tumors. Overall,
these data demonstrate commonality among the gcGBMs
that exhibit this massive LOH and may indicate that this
signature represents a distinct molecular subtype of
these tumors.
Our results substantiate a single case report from nearly
35 years ago which originally describe near-haploidy in a
gcGBM16 and highlights this observation as a reproducible, and likely defining molecular hallmark of a subset of
these tumors. Our study thus represents the first allelicspecific copy number analysis of a morphologically homogeneous tumor cohort. We suspect that future studies
employing this approach will identify additional gcGBMs
with near haploidy. While recent studies highlighted a copy
number and mutational profile similar to our cohort, they
lacked allelic-specific copy number analyses.5,6 Our study

Baker et al. Near haploidization characterizes gcGBM

Supplementary material is available at Neuro-Oncology
Advances online.

giant cell glioblastoma | glioblastoma | loss of heterozygosity | near haploidization

Funding
This work was supported by the Children’s Mercy Cancer Center
[FP00001036 to L.D.C.].

Conflict of interest statement. Y.Y.L. reports equity in g.Root
Biomedical Services.

Authorship Statement: Data acquisition, writing, formatting, and
critical review of the manuscript: T.G.B., J.A., A.M.D., D.J.W.,
and D.M.M. Neuropathology review: C.T.W., M.G., and D.M.M.
Microarray data analysis: I.Z. and L.D.C. Case contribution:
L.D.C., M.S.F, and S.S. TCGA data analysis: Y.Y.L. and A.D.C.
Acquisition and review of clinical data: S.M.L. Study conception:
D.J.W.

References
1.

2.

3.

4.

5.

6.

7.

8.

Louis DN, Ohgaki H, Wiestler OD, et al., eds. WHO Classification of
Tumours of the Central Nervous System. Revised 4th ed. Lyon, France:
International Agency for Research on Cancer; 2016.
Kozak KR, Moody JS. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol.
2009;11(6):833–841.
Ortega A, Nuño M, Walia S, Mukherjee D, Black KL, Patil CG. Treatment
and survival of patients harboring histological variants of glioblastoma.
J Clin Neurosci. 2014;21(10):1709–1713.
Jin MC, Wu A, Xiang M, et al. Prognostic factors and treatment patterns in the management of giant cell glioblastoma. World Neurosurg.
2019;128:e217–e224.
Cantero D, Mollejo M, Sepúlveda JM, et al. TP53, ATRX alterations,
and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neurooncol Adv.
2020;2(1):vdz059.
Shi ZF, Li KK, Kwan JSH, et al. Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. Brain Pathol.
2019;29(6):782–792.
Barresi V, Simbolo M, Mafficini A, et al. Ultra-mutation in IDH wild-type
glioblastomas of patients younger than 55 years is associated with defective mismatch repair, microsatellite instability, and giant cell enrichment. Cancers (Basel). 2019;11(9):1279.
Vande Perre P, Siegfried A, Corsini C, et al. Germline mutation p.N363K
in POLE is associated with an increased risk of colorectal cancer and
giant cell glioblastoma. Fam Cancer. 2019;18(2):173–178.

Downloaded from https://academic.oup.com/noa/article/2/1/vdaa155/5979493 by guest on 12 January 2021

Supplementary Material

Keywords

Neuro-Oncology
Advances

Recent genomic studies, however, demonstrate the
nearly universal presence of homozygous CDKN2A deletion and mitogen-activated protein kinase (MAPK)
activating alterations, most commonly in BRAF,12,25,26
neither of which were observed in any of our gcGBMs.
Furthermore, this pattern of near haploidization has
not been described in PXA and serves as a useful diagnostic adjunct in cases where this differential diagnosis
is being considered, further highlighted by our ability to
identify 3 cases of gcGBM from the TCGA GBM cohort by
genomic signature alone.
The importance of appropriately defining this entity
stems from the need to characterize the clinical significance of this observation. Previous reports suggest that
gcGBMs may demonstrate a survival advantage as compared to their non-gcGBM counterparts2–5,11; however, the
limited follow-up data and recent identification of many of
the diagnoses in our cohort precludes definitive assessment of outcomes associated with near haploidization.
Nonetheless, it is possible that the frequently wellcircumscribed nature of gcGBMs is more amenable to
gross total surgical resections and thus improved outcomes. It is also worth noting the prominent inflammatory
component in these tumors which may present an attractive target for immunotherapy. While recent phase 3 trials
investigating the efficacy of immune therapy in glioblastoma have shown disappointing results,27 GBM in general
is immunologically quiet with minimal lymphocytic infiltrates compared to other tumors that have been successfully treated with immune checkpoint blockade.28 Similar
to inflammatory leiomyosarcomas, it is possible that near
haploidization in gcGBM induces a pro-inflammatory state,
which in turn may confer improved response to conventional therapies, but further study is clearly needed.
In summary, gcGBM is a rare subtype of IDH-wildtype
GBM, currently diagnosed solely on histomorphology. As
a group, these tumors are distinguished from their nongcGBM counterparts by a slightly improved prognosis,
decreased overall mutational burden, increased frequency
of specific genetic variants, such as TP53, and decreased
focal copy number changes. These molecular features
are not specific enough to confirm the diagnosis for individual cases. We present herein a cohort of gcGBMs with
near-haploidy, including massive LOH and retention of
chromosome 7 heterozygosity, which when associated
with giant cell morphology, represents the genomic hallmark of these entities and aids in their identification for
investigative and diagnostic purposes. Future studies with
larger cohorts and patient outcome data are necessary to
refine molecular criteria required for their more accurate
diagnosis, as well as to determine if the subset of gcGBM
described herein is distinctive beyond the molecular features, particularly regarding patient outcome and therapeutic response.
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